NCT02583009

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Anti Rosacea Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Rosacea Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 216 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 0.1%	Topical application
DRUG	PAC-14028 cream 0.3%	Topical application
DRUG	PAC-14028 cream 1.0%	Topical application
DRUG	PAC-14028 cream vehicle	Topical application

Timeline

• Start date: 2014-10-01
• Primary completion: 2016-08-01
• First posted: 2015-10-21
• Last updated: 2016-09-20

Locations

1 site across 1 country: South Korea